| 本文已被：浏览 次 下载 次 |
|
|
|
| 骨髓细胞DNA倍体及增殖周期的检测在骨髓增生异常综合征诊断中的作用 |
|
李瑞华1, 何晓琳1, 石宏晏1, 赵桂云2
|
|
1.大连医科大学,第二临床学院,检验科,辽宁,大连,116027;2.旅顺口区人民医院,检验科,辽宁,大连,116041
|
|
| 摘要: |
| [目的] 探讨DNA倍体及增殖周期在骨髓异常增生综合征(MDS)的变化及意义.[方法] 应用流式细胞仪(FCM)测定MDS组和良性血液病组骨髓细胞的DNA倍体及增殖周期.[结果] 良性血液病组无一例检出DNA非整倍体,MDS组DNA非整倍体检出率(25.7%)明显高于对照组.MDS组骨髓细胞G0/G1期百分比明显高于对照组(P<0.05),S+G2/M期百分比明显低于对照组(P<0.05).[结论]流式细胞仪DNA倍体及周期分析是MDS一个重要的诊断指标,对于MDS的疗效、预后判断有重要的意义. |
| 关键词: 骨髓增生异常综合征 DNA非整倍体 增殖周期 |
| DOI：10.11724/jdmu.2003.01.20 |
| 分类号:R446.1 |
| 基金项目: |
|
| Analysis of bone marrow DNA ploidy and proliferation period in myelodysplastic syndromes |
|
LI Rui-hua1, HE Xiao-lin1, SHI Hong-yan1, ZHAO Gui-yun2
|
|
1.Department of Laboratory Medicine, the Second Affiliated Hospital of Dalian Medical University, Dalian 116027, China;2.Lüshunkou District People's Hospital, Dalian 116041, China)
|
| Abstract: |
| To study the variation and significance of DNA anueploidy and proliferation period in myelodysplastic syndromes(MDS).［Method］ The bone marrow cell of MDS group and non-malignant hematologic disease (served as control) were evaluated by flow cytometry. ［Result］ The incidence of FCM-DNA aneuploidy was 25.7% in MDS patients and zero in the control group. The percentage of the bone marrow cells in MDS is remarkable higher than that of the control groups at G0/G1 stage （P<0.05）, but markedly lower than that of the control group at (S+G2/M) stage （P<0.05）. ［Conclusion］ FCM-DNA Aneuploidy is a new diagnostic and prognostic factor in MDS |
| Key words: DNA MDS proliferation period |